Statistical analyses considered the clinical and laboratory data collected at the time of documented disease transformation from PV to post-PV MF or from ET to post-ET MF. Survival was calculated from the date of disease transformation to the date of death or last contact.
A total of 125 patients with post-PV (n = 79) or post-ET (n = 46) MF were studied (median age 62 years; 50% females); percentages of patients were 46% for age 465 years, 44% for hemoglobin o10 g/dl, 19% for red cell transfusion need, 19% for leukocyte count 425 × 10(9)/l, 14% for platelet count o100 × 10(9)/l, 45% for circulating blasts X1%, 38% for constitutional symptoms and 17% for unfavorable karyotype. Risk distribution of the 125 patients with post-PV/ET MF, according to IPSS, was high in 39 (31%) patients, intermediate-2 in 40 (32%), intermediate-1 in 30 (24%) and low in 16 (13%); the corresponding percentages for DIPSS were 10, 38, 38 and 13%, and for DIPSS-plus 26, 41, 21 and 12%. Comparison of patients with post-PV and post-ET MF disclosed higher hemoglobin level (P = 0.002), higher leukocyte count (P = 0.0007) and larger palpable spleen size (P = 0.002) in post-PV MF.
After a median follow-up of 3 years, from the date of fibrotic progression, 86 (69%) deaths and 10 (8%) leukemic transformations were documented. Multivariable analysis, which included the 5 aforementioned risk variables used in IPSS or DIPSS, disclosed independent predictive value for shortened survival, for all but constitutional symptoms: HR (95% CI; P-value) were 2.6 (1.6-4.2; P o0.0001) for age 465 years, 2.2 (1.4-3.5; P = 0.001) for circulating blasts ⩾ 1%, 1.8 (1.1-2.8; P = 0.01) for hemoglobin o10 g/dl, 1.8 (1.1-3.1; P = 0.02) for leukocyte count 425 × 10(9)/l and 1.2 (0.7-1.9; P = 0.5) for constitutional symptoms. Similarly, multivariable analysis that included all eight risk variables used in DIPSS-plus disclosed significant predictive value for all except constitutional symptoms (P = 0.9) and leukocyte count 425 × 10 (9)/l with borderline significance (P = 0.06).
Application of IPSS, DIPSS and DIPSS-plus, to the 125 study patients with post-ET/PV MF is outlined in Figure 1 . HR (95% CI) using IPSS were 2. The spirit of our observations is somewhat different than that echoed by our respected colleagues from Italy regarding their recently published new prognostic system for post-ET/PV MF. 7 In the particular study, the authors found constitutional symptoms to retain its significance, along with anemia, thrombocytopenia, advanced age, circulating blasts and absence of CALR mutations, and used these variables to devise a newly-proposed prognostic model. Although the effort to include molecular markers is laudable, it might have been truncated in this instance because of the absence of information on other mutations known to affect outcome in PMF, such as ASXL1 and SRSF2. 8 On the other hand, considering the fact that virtually all patients with post-PV MF are JAK2-mutated, one can argue the appropriateness of using driver mutational status, as a variable for a risk model, in post-PV MF. Consistent with these reservations, another recent study of 359 patients with post-ET/PV MF did not find a survival impact from either the type of driver mutation or its allele burden; 9 instead, the study reported a detrimental effect of triple-negative driver mutational status and SRSF2 mutations in post-ET MF only. From a practical standpoint, our observations provide the evidence to support the use of IPSS/DIPSS/DIPSS-plus in post-PV/ET MF, thus maintaining familiarity and uniformity, until a molecularly more robust system is developed. 
